Retrogenix, the Derbyshire-based early-stage contract research organisation (CRO) providing specialised bioanalytical services, has been acquired by Charles River Laboratories.
Charles River is a global CRO providing drug discovery and development services. The acquisition further strengthens its integrated end-to-end solution for therapeutic antibody, and cell and gene therapy discovery and development.
Employing 18,000 professionals at over 100 sites worldwide, the company has participated in the development of 80% of the drugs approved by the FDA over the last 3 years.
Wilbert Frieling, Corporate Senior Vice President, Global Discovery Services, Charles River, said: “We are delighted to add Retrogenix’s highly effective cell screening service to Charles River’s integrated offering.
“Coupled with our comprehensive drug discovery service portfolio, Retrogenix’s novel cell microarray technology and library of plasma membrane and secreted protein clones will allow us to support our clients by informing early drug discovery efforts and providing preclinical safety assurance.”
Retrogenix will continue to operate from its High Peak facilities, and there will be no changes to its workforce.
Dr Jim Freeth, Co-Founder, Retrogenix, said: “Joining Charles River is a very exciting step for Retrogenix, allowing us to integrate into a comprehensive service supporting the entire CRO development pipeline. With Charles River’s support, we are looking forward to accelerating our growth and technological development.”